

# Ombretta Viapiana

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8099197/publications.pdf>

Version: 2024-02-01

122  
papers

3,095  
citations

136740

32  
h-index

197535

49  
g-index

127  
all docs

127  
docs citations

127  
times ranked

3898  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 758-763.	3.1	191
2	The obesity paradox and osteoporosis. <i>Eating and Weight Disorders</i> , 2018, 23, 293-302.	1.2	142
3	Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. <i>Bone</i> , 2008, 42, 267-270.	1.4	99
4	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , 2016, 35, 1281-1286.	1.0	95
5	Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. <i>PLoS Medicine</i> , 2019, 16, e1002901.	3.9	94
6	Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2259-2263.	3.1	87
7	The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1555-1559.	1.8	82
8	Osteoporosis in Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5867.	1.8	76
9	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2016, 7, 380.	1.6	72
10	Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight. <i>Bone</i> , 2007, 40, 1073-1077.	1.4	69
11	Teriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I. <i>Calcified Tissue International</i> , 2013, 93, 448-452.	1.5	68
12	Physical Activity and Bone Turnover Markers: A Cross-Sectional and a Longitudinal Study. <i>Calcified Tissue International</i> , 2008, 83, 388-392.	1.5	64
13	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2018, 37, 2233-2240.	1.0	64
14	Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. <i>Bone</i> , 2012, 50, 739-742.	1.4	63
15	Long-Term Effects of Amino-Bisphosphonates on Circulating $\gamma\delta$ T Cells. <i>Calcified Tissue International</i> , 2012, 91, 395-399.	1.5	61
16	Sclerostin and DKK1 in Primary Hyperparathyroidism. <i>Calcified Tissue International</i> , 2013, 92, 324-329.	1.5	57
17	Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients. <i>Calcified Tissue International</i> , 2017, 101, 17-23.	1.5	52
18	Safety issues and adverse reactions with osteoporosis management. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 321-332.	1.0	50

#	ARTICLE	IF	CITATIONS
19	In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 77-83.	0.4	50
20	Strong relationship between vitamin D status and bone mineral density in anorexia nervosa. <i>Bone</i> , 2015, 78, 212-215.	1.4	49
21	Bisphosphonates vs infliximab in ankylosing spondylitis treatment. <i>Rheumatology</i> , 2014, 53, 90-94.	0.9	47
22	Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis. <i>Calcified Tissue International</i> , 2016, 98, 438-445.	1.5	46
23	Association between environmental air pollution and rheumatoid arthritis flares. <i>Rheumatology</i> , 2021, 60, 4591-4597.	0.9	43
24	Circulating $\hat{\text{T}}$ T cells and the risk of acute-phase response after zoledronic acid administration. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 227-230.	3.1	41
25	Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab. <i>Bone</i> , 2016, 92, 150-156.	1.4	40
26	Focal bone involvement in inflammatory arthritis: the role of IL17. <i>Rheumatology International</i> , 2016, 36, 469-482.	1.5	40
27	Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis. <i>Calcified Tissue International</i> , 2016, 99, 360-364.	1.5	39
28	In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls. <i>Clinical Rheumatology</i> , 2017, 36, 2377-2381.	1.0	38
29	Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid. <i>Rheumatology</i> , 2009, 48, 773-778.	0.9	37
30	The Association between Weight Gain/Restoration and Bone Mineral Density in Adolescents with Anorexia Nervosa: A Systematic Review. <i>Nutrients</i> , 2016, 8, 769.	1.7	35
31	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	1.6	35
32	Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women. <i>Bone</i> , 2010, 46, 244-247.	1.4	34
33	Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial. <i>Rheumatology International</i> , 2015, 35, 255-263.	1.5	34
34	Zoledronic Acid in Osteoporosis Secondary to Mastocytosis. <i>American Journal of Medicine</i> , 2014, 127, 1127.e1-1127.e4.	0.6	31
35	Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis. <i>Pharmacological Research</i> , 2019, 147, 104354.	3.1	30
36	Osteoporosis in 10 years time: a glimpse into the future of osteoporosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210835.	1.2	30

#	ARTICLE	IF	CITATIONS
37	18F-fluoride PET/CT for detection of axial involvement in ankylosing spondylitis: correlation with disease activity. <i>Annals of Nuclear Medicine</i> , 2016, 30, 430-434.	1.2	29
38	Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. <i>Nutrients</i> , 2020, 12, 1553.	1.7	29
39	Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study. <i>RMD Open</i> , 2022, 8, e002055.	1.8	29
40	Acute Phase Response After Zoledronic Acid is Associated with Long-Term Effects on White Blood Cells. <i>Calcified Tissue International</i> , 2013, 93, 249-252.	1.5	27
41	New Strategies for the Prevention and Treatment of Systemic and Local Bone Loss; from Pathophysiology to Clinical Application. <i>Current Pharmaceutical Design</i> , 2018, 23, 6241-6250.	0.9	27
42	Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series. <i>Calcified Tissue International</i> , 2017, 100, 595-598.	1.5	26
43	Bone Disease in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2018, 38, 443-454.	0.7	25
44	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 918.	1.6	25
45	The ultrasonographic study of the nail reveals differences in patients affected by inflammatory and degenerative conditions. <i>Clinical Rheumatology</i> , 2019, 38, 913-920.	1.0	25
46	An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 1059-1062.	0.9	25
47	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- $\alpha$ Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-12.	1.4	24
48	Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. <i>Medical Ultrasonography</i> , 2018, 20, 177.	0.4	23
49	Neridronic acid for the treatment of bone metabolic diseases. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 1305-1311.	1.5	21
50	Clinical development of neridronate: potential for new applications. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 139.	0.9	21
51	Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis. <i>Calcified Tissue International</i> , 2016, 98, 580-585.	1.5	21
52	Vitamin D levels strongly influence bone mineral density and bone turnover markers during weight gain in female patients with anorexia nervosa. <i>International Journal of Eating Disorders</i> , 2017, 50, 1041-1049.	2.1	21
53	Gender disparity in authorship of guidelines and recommendations in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1122-1123.	0.5	21
54	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	1.2	21

#	ARTICLE	IF	CITATIONS
55	Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis. <i>Bone</i> , 2014, 67, 189-192.	1.4	20
56	Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 133-136.	0.4	20
57	Denosumab, cortical bone and bone erosions in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e70-e70.	0.5	18
58	Osteoporosis in Inflammatory Arthritides: New Perspective on Pathogenesis and Treatment. <i>Frontiers in Medicine</i> , 2020, 7, 613720.	1.2	18
59	The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders. <i>Frontiers in Endocrinology</i> , 2021, 12, 620920.	1.5	18
60	Clinical profile and outcome of patients with rheumatoid arthritis and abnormally high aortic stiffness. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1848-1859.	0.8	16
61	Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2018, 37, 3093-3098.	1.0	16
62	Dickkopf-1 and Sclerostin Serum Levels in Patients with Systemic Mastocytosis. <i>Calcified Tissue International</i> , 2015, 96, 410-416.	1.5	15
63	Economic evaluation of spondyloarthritis: economic impact of diagnostic delay in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 45-51.	0.7	15
64	Acute Effects of Glucocorticoid Treatment, TNF $\pm$ or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study. <i>Calcified Tissue International</i> , 2020, 106, 371-377.	1.5	15
65	Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros. <i>Endocrine</i> , 2015, 49, 620-627.	1.1	14
66	Osteoporosis: an Independent Determinant of Bone Erosions in Rheumatoid Arthritis?. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2142-2143.	3.1	14
67	The use of bisphosphonates in women: when to use and when to stop. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2409-2421.	0.9	13
68	Vitamin D serum levels and the risk of digital ulcers in systemic sclerosis: A longitudinal study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1041-1045.	0.9	13
69	Environmental Air Pollution Is a Predictor of Poor Response to Biological Drugs in Chronic Inflammatory Arthritides. <i>ACR Open Rheumatology</i> , 2021, 3, 451-456.	0.9	13
70	Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 933-935.	1.5	12
71	Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates. <i>Journal of Rheumatology</i> , 2019, 46, 318-322.	1.0	12
72	Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease. <i>Clinical Rheumatology</i> , 2017, 36, 2487-2495.	1.0	11

#	ARTICLE	IF	CITATIONS
73	Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed "window of opportunity". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e181-e181.	0.5	11
74	Factors associated with referral for osteoporosis care in men: a real-life study of a nationwide dataset. <i>Archives of Osteoporosis</i> , 2021, 16, 56.	1.0	11
75	The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes. <i>Journal of Bone and Mineral Research</i> , 2021, 36, 2177-2183.	3.1	11
76	Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone. <i>Clinical Rheumatology</i> , 2017, 36, 925-928.	1.0	10
77	Long-Term Effects of Neridronate and its Discontinuation in Patients with Primary Hyperparathyroidism. <i>Calcified Tissue International</i> , 2011, 89, 21-28.	1.5	9
78	Effects of denosumab on peripheral lymphocyte subpopulations. <i>Endocrine</i> , 2016, 53, 857-859.	1.1	9
79	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 1018-1028.	0.4	8
80	Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. <i>Cancers</i> , 2019, 11, 30.	1.7	7
81	Relationship Between Increased Fecal Calprotectin Levels and Interstitial Lung Disease in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 274-278.	1.0	7
82	Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e150-e150.	0.5	7
83	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-6.	1.4	7
84	Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 570-571.	3.1	7
85	CD14 <sup>++</sup> CD16 <sup>+</sup> monocytes are the main source of IL-1 $\beta$ -HSD type 1 after IL-4 stimulation. <i>International Immunopharmacology</i> , 2017, 43, 156-163.	1.7	6
86	Wnt Inhibitors and Bone Turnover Markers in Patients With Polymyalgia Rheumatica and Acute Effects of Glucocorticoid Treatment. <i>Frontiers in Medicine</i> , 2020, 7, 551.	1.2	6
87	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome: Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. <i>Frontiers in Medicine</i> , 2021, 8, 668173.	1.2	6
88	Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options. <i>Clinical Rheumatology</i> , 2022, 41, 1247-1254.	1.0	6
89	An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 107-114.	0.4	6
90	Prednisone compared to methylprednisolone in the polymyalgia rheumatica treatment. <i>Rheumatology International</i> , 2015, 35, 735-739.	1.5	5

#	ARTICLE	IF	CITATIONS
91	Rheumatoid arthritis, $\hat{I}^3\hat{I}^T$ T cells and bisphosphonates. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e57-e57.	0.5	5
92	Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 863-874.	1.0	5
93	Correspondence on <i>Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry</i> ™ by Gianfrancesco <i>et al</i> . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e222-e222.	0.5	4
94	Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 158.	1.6	4
95	Could $\hat{I}^3\hat{I}^T$ T Cells Explain Adverse Effects of Zoledronic Acid? Comment on the Article by Reinhardt et al. <i>Arthritis and Rheumatology</i> , 2017, 69, 1339-1339.	2.9	3
96	Ultrasonography involvement of carotid, upper and lower limb arteries in a large cohort of systemic sclerosis patients. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 681-692.	0.9	3
97	Sex-Specific Association of Left Ventricular Hypertrophy With Rheumatoid Arthritis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 676076.	1.1	3
98	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	3
99	Disease activity and left ventricular systolic function in rheumatoid arthritis: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e83-e83.	0.5	2
100	Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?. <i>Arthritis Research and Therapy</i> , 2018, 20, 233.	1.6	2
101	Usefulness of CHA2DS2-VASc score to predict mortality and hospitalization in patients with inflammatory arthritis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 106-115.	0.9	2
102	Could Previous Exposure to Nitrogen-Containing Bisphosphonates Mitigate Friendly Fire?. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 2082-2082.	3.1	2
103	Pharmacodynamics of Oral Cholecalciferol in Healthy Individuals with Vitamin D Deficiency: A Randomized Open-Label Study. <i>Nutrients</i> , 2021, 13, 2293.	1.7	2
104	Rituximab increases peripheral natural killer cells in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 241-246.	0.4	2
105	Acute Phase Reaction and Fracture Risk Reduction: Are Gamma-Delta T Cells and Hypovitaminosis D the Missing Link?. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1622-1622.	3.1	2
106	Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211050.	1.2	2
107	DXA bone mineral density in males: retrospective study in real life. <i>Aging Clinical and Experimental Research</i> , 2015, 27, 425-430.	1.4	1
108	Treatment with secukinumab in multi-comorbid patients with psoriatic arthritis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 9-11.	1.1	1

#	ARTICLE	IF	CITATIONS
109	Very low reporting rate of connective tissue diseases among coronavirus disease 2019 (Covid-19) patients and the renin-angiotensin system – An overlooked association?. <i>European Journal of Internal Medicine</i> , 2020, 80, 106-107.	1.0	1
110	Response to: –Correspondence on –Gender disparity in authorship of guidelines and recommendations in rheumatology–™™ by Stewart et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-219305.	0.5	1
111	Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17. <i>Clinical Drug Investigation</i> , 2022, 42, 103.	1.1	1
112	Incidence and predictors of adverse clinical events in patients with rheumatoid arthritis and asymptomatic left ventricular systolic dysfunction. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 420-427.	0.4	1
113	Relationship between common carotid distensibility/aortic stiffness and cardiac left ventricular morphology and function in a group of patients affected by chronic rheumatic diseases: an observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 344-350.	0.4	1
114	AB0831 –...PERSPECTIVE ON THE CLINICAL PRACTICE MANAGEMENT OF HYPOVITAMINOSIS D FROM A MEETING OF ITALIAN EXPERTS. , 2019, , .		0
115	AB0370 –...EFFICACY AND SAFETY OF BIOLOGIC TREATMENT IN ELDERLY RHEUMATOID ARTHRITIS PATIENTS: A WIDE COHORT STUDY. , 2019, , .		0
116	Left ventricular hypertrophy predicts poorer cardiovascular outcome in normotensive normoglycemic patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 510-518.	0.9	0
117	The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2021, 23, 89.	1.6	0
118	Comment on: clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 548.	0.4	0
119	Relationship between common carotid distensibility/aortic stiffness and cardiac left ventricular morphology and function in a group of patients affected by chronic rheumatic diseases: an observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 344-350.	0.4	0
120	Real-world Coronavirus disease-19 vaccine hesitancy in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	0
121	Retention rate of IL-1 inhibitors in Schnitzler's syndrome.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
122	Real-world Coronavirus disease-19 vaccine hesitancy in systemic sclerosis.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0